World J Mens Health.  2015 Dec;33(3):167-173. 10.5534/wjmh.2015.33.3.167.

Dyslipidemia Prevalence in Iranian Adult Men: The Impact of Population-Based Screening on the Detection of Undiagnosed Patients

• Mohammadbeigi A
• Moshiri E
• Mohammadsalehi N
• Ansari H
• Ahmadi A

• KMID: 2405144
• DOI: http://doi.org/10.5534/wjmh.2015.33.3.167

Abstract

PURPOSE
Dyslipidemia has been established as one of the most important modifiable risk factors for cardiovascular disease. Due to the higher prevalence of dyslipidemia in males, this study aimed to estimate the prevalence of dyslipidemia in Iranian urban men.
MATERIALS AND METHODS
A screening program was conducted in 845 Iranian men 25 years of age and older in 2014. A health interview survey was conducted to evaluate the prevalence of self-reported dyslipidemia and to collect demographic data, as well as serum lipid profile screening by a reference laboratory. Lipoprotein levels was categorized based on the Adult Treatment Panel III criteria and the data were analyzed using the chi-square test and analysis of variance.
RESULTS
The overall prevalence of dyslipidemia was 51.8%, and the prevalence of various forms of dyslipidemia was as follows: hypercholesterolemia (> or =240 mg/dL), 11.4%; hyper-low-density lipoprotein cholesterol (> or =160 mg/dL), 9.6%; hypertriglyceridemia (> or =200 mg/dL), 25%; and hypo-high-density lipoprotein (HDL) cholesterol (<40 mg/dL), 34.3%. With the exception of hypo-HDL, all forms of dyslipidemia were significantly less common in men over 65 years of age (p<0.05).
CONCLUSIONS
The prevalence of hypo-HDL and hypertriglyceridemia was higher than expected in Iranian adult men, with half of men 25 years of age and older affected by at least one form of dyslipidemia. A large gap in primary and secondary care was observed, because nearly 80% of patients with dyslipidemia were unaware of their status. Urgent preventive programs and lifestyle changes are necessary to reduce the prevalence of cardiovascular risk factors.

Keyword

Dyslipidemia; Hypercholesterolemia; Hypertriglyceridemia; Male; Metabolic diseases

MeSH Terms

Adult*
Cardiovascular Diseases
Cholesterol
Dyslipidemias*
Humans
Hypercholesterolemia
Hypertriglyceridemia
Life Style
Lipoproteins
Male
Mass Screening*
Metabolic Diseases
Prevalence*
Risk Factors
Secondary Care
Cholesterol
Lipoproteins

Reference

1. Sawant AM, Shetty D, Mankeshwar R, Ashavaid TF. Prevalence of dyslipidemia in young adult Indian population. J Assoc Physicians India. 2008; 56:99–102.

2. Petrella RJ, Merikle E, Jones J. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. Clin Ther. 2007; 29:742–750.

3. Hassanzadeh J, Mohammadbeigi A, Eshrati B, Moemenbellah-Fard MD. Estimation of the regional burden of non-communicable diseases due to obesity and overweight in Markazi province, Iran, 2006-2007. J Cardiovasc Dis Res. 2012; 3:26–31.

4. Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014; 8:206–216.

5. AlMajed HT, AlAttar AT, Sadek AA, AlMuaili TA, AlMutairi OA, Shaghouli AS, et al. Prevalence of dyslipidemia and obesity among college students in Kuwait. Alex J Med. 2011; 47:67–71.

6. Posadas-Sánchez R, Posadas-Romero C, Zamora-González J, Mendoza-Pérez E, Cardoso-Saldaña G, Yamamoto-Kimura L. Lipid and lipoprotein profiles and prevalence of dyslipidemia in Mexican adolescents. Metabolism. 2007; 56:1666–1672.

7. Lee MH, Kim HC, Ahn SV, Hur NW, Choi DP, Park CG, et al. Prevalence of dyslipidemia among Korean adults: Korea National Health and Nutrition Survey 1998-2005. Diabetes Metab J. 2012; 36:43–55.

8. Florez H, Silva E, Fernández V, Ryder E, Sulbarán T, Campos G, et al. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res Clin Pract. 2005; 69:63–77.

9. Yadav D, Mishra M, Tiwari A, Bisen PS, Goswamy HM, Prasad GB. Prevalence of dyslipidemia and hypertension in Indian type 2 diabetic patients with metabolic syndrome and its clinical significance. Osong Public Health Res Perspect. 2014; 5:169–175.

10. Zahid N, Claussen B, Hussain A. High prevalence of obesity, dyslipidemia and metabolic syndrome in a rural area in Pakistan. Diabete Metab Syndr Clin Res Rev. 2008; 2:13–19.

11. Khader YS, Batieha A, El-Khateeb M, Al Omari M, Ajlouni K. Prevalence of dyslipidemia and its associated factors among Jordanian adults. J Clin Lipidol. 2010; 4:53–58.

12. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289:76–79.

13. Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine. 2008; 34:36–51.

14. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008; 156:112–119.

15. Chang HY, Yeh WT, Chang YH, Tsai KS, Pan WH. Prevalence of dyslipidemia and mean blood lipid values in Taiwan: results from the Nutrition and Health Survey in Taiwan (NAHSIT, 1993-1996). Chin J Physiol. 2002; 45:187–197.

16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–2497.

17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143–3421.

18. Khan NI, Naz L, Mushtaq S, Rukh L, Ali S, Hussain Z. Ischemic stroke: prevalence of modifiable risk factors in male and female patients in Pakistan. Pak J Pharm Sci. 2009; 22:62–67.

19. Hassanzadeh J, Mohammadbeigi A, Eshrati B, Rezaianzadeh A, Rajaeefard A. Determinants of inequity in health care services utilization in markazi province of iran. Iran Red Crescent Med J. 2013; 15:363–370.

20. Kavosi Z, Mohammadbeigi A, Ramezani-Doroh V, Hatam N, Jafari A, Firoozjahantighi A. Horizontal inequity in access to outpatient services among Shiraz City residents, Iran. J Res Health Sci. 2015; 15:37–41.

21. Mohammadbeigi A, Arsangjang S, Mohammadsalehi N, Anbari Z, Ghaderi E. Education-related inequity in access and utilization of oral health care in Iran. J Family Med Prim Care. 2015; 4:35–38.

22. Mohammadbeigi A, Hassanzadeh J, Eshrati B, Mohammadsalehi N. Inequity in health; measurement indexes and application to the health care utilization data. Iran J Epidemiol. 2013; 9:1–14.

23. Mohammadbeigi A, Hassanzadeh J, Eshrati B, Rezaianzadeh A. Socioeconomic inequity in health care utilization, Iran. J Epidemiol Glob Health. 2013; 3:139–146.

24. Mohammadbeigi A, Hassanzadeh J, Eshrati B, Rezaianzadeh A. Decomposition of inequity determinants of healthcare utilization, Iran. Public Health. 2013; 127:661–667.

25. Sharifi F, Mousavinasab SN, Soruri R, Saeini M, Dinmohammadi M. High prevalence of low high-density lipoprotein cholesterol concentrations and other dyslipidemic phenotypes in an Iranian population. Metab Syndr Relat Disord. 2008; 6:187–195.